(SOURCE: MASSACHUSETTS GENERAL HOSPITAL) – A nearly two-decades-long clinical trial has demonstrated that adding antiandrogen therapy to radiation therapy can improve the survival of prostate cancer patients who have evidence of disease recurrence after radical prostatectomy. The study conducted by the NRG Oncology Radiation Therapy Oncology Group appears in the February 2 New England Journal of […]
(SOURCE: UNIVERSITY HEALTH NETWORK) – Canadian prostate cancer researchers have discovered the genetic fingerprint that explains why up to 30 per cent of men with potentially curable localized prostate cancer develop aggressive disease that spreads following radiotherapy or surgery. The findings, published online today in Nature, could help clinicians personalize effective, targeted therapies from the moment of […]
(SOURCE: UNIVERSITY OF MICHIGAN HEALTH SYSTEM) – But among those diagnosed, treatment rates remain high, despite increasing evidence that surveillance may be appropriate option. As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds. The decline reflects efforts to […]
(SOURCE: SOCIETY OF NUCLEAR MEDICINE) – A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). The study is published in the January 2017 issue of The Journal of Nuclear Medicine and […]
(SOURCE: SCRIPPS RESEARCH INSTITUTE) – A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer. The researchers found that targeting the components of this circuit suppresses advanced prostate cancer development. The study, led by TSRI Associate […]
(SOURCE: GEORGETOWN UNIVERSITY MEDICAL CENTER) – For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses. The achievement, say researchers at Georgetown University Medical Center who […]
(SOURCE: UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS) – Starting in 1993 and ending in 2001, ten academic medical centers in the United States screened 76,685 men and 78,216 women for prostate, lung, colorectal and ovarian cancers. The question was whether yearly screening could catch cancers early and thus decrease mortality from these diseases. Fifteen-year follow-up results focusing […]
(SOURCE: JOHN’S HOPKINS MEDICINE) Technique shows promise in increasing accuracy of prostate and breast cancer treatment in people. An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen […]
(THE WISTAR INSTITUTE) According to a recent press release, scientists at The Wistar Institute have demonstrated how a protein called TRAP1 – an important regulator of energy production in healthy and cancerous cells – is an important driver of prostate cancer and appears to be a valuable therapeutic target for the disease. The findings were […]
(CANCER RESEARCH UK) According to a recent press release, researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
(University of Missouri) According to an article recently published by the University of Missouri, researchers at the Cancer Research Center (CRC) in Columbia have discovered they can use a genetically modified strain of Salmonella bacteria to target cancer cells.
(Men’s Journal) According to an article published in Men’s Journal reviewing a new study published in JAMA Oncology, androgen deprivation therapy (ADT), a common treatment for prostate cancer may double risk of dementia.
(PRNewswire) Astellas Pharma Inc. and Pfizer Inc. recently announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with […]
(PRNewswire-USNewswire) – According to a recent press release, a new report on Swedish men with non-aggressive prostate cancer suggests that a lot more American men could safely choose to monitor their disease instead of seeking immediate radiation treatment or surgery.
(Fox News) According to a recent article published in Fox News.com, men with prostate cancer may be more likely to have the most serious form of the cancer if their diet contains a significant amount of fat from meat and dairy, a recent U.S. study suggests.
(NY Times) According to a recent study and article published in the NYTimes.com, reducing testosterone levels in men with standard androgen deprivation therapy, or A.D.T., a common treatment for prostate cancer, more than doubles the risk of dementia.
(Fox News) A recent story published in Fox News reports that when Maddie Demers’ rare metastatic bone cancer (Multicentric Osteosarcoma) stopped responding to conventional chemotherapy in June, her oncologist advised her parents, Barbie and Mike, to put her under hospice care. However recently, following three rounds of a targeted radiation traditionally used to treat prostate […]
(MayoClinic.org) According to a recent article from the Mayo Clinic, a team of researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery.
(CNBC) According to a recent article published in CNBC.com, close to a dozen new medical tests using blood, urine and tissue samples are coming to market that aim to more accurately diagnose prostate cancer and go well beyond the standard PSA (prostate-specific antigen) blood screenings used today.
According to a study published recently in the New England Journal of Medicine, there is strong evidence that waiting and monitoring is a reasonable approach for most men with prostate cancer. In the study, British scientists carefully monitored the progress of more than 1600 men with prostate cancer for a period of 10 years. The men were classified […]